[1] – 1991 (10/4/1991) – Site visit – Antineoplaston Cases

This page is linked to:
Critiquing: Dr. Michael A. Friedman, Dr. Mark G. Malkin, Dr. Mario Sznol, Robert B. Lanman, Memorial Sloan-Kettering Cancer Center, Mayo Clinic, Department of Health & Human Services (HHS), Public Health Service, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Center (NCI) at the National Institutes of Health (NIH), Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies
[1] – 1991 (10/4/1991) – Site visit – Antineoplaston Cases (1 pg.)
1. Histology partial lobe glioblastoma multiforme (GBM)
Size 2.3 cm largest diameter
Response Complete Response (CR) possible
prior Treatment (Tx) Radiation Therapy (RT), surgery

2. Histology anaplastic astrocytoma stage IV grade 3
Size 3.0 tumor 3.5 tumor and edema
Response CR possible
prior Treatment (Tx) Radiation Therapy (RT)

3. Histology infiltrating glioma (astrocytoma or mixed astrocytoma / oligodendroglioma)
Size 4.4
Response good PR, possible CR
prior Treatment (Tx) Radiation Therapy (RT) and BUdR; Procarbazine, CCNU, VCR; B-Interferon; DFMO and MGBG

4. Histology well differentiated Stage IV astrocytoma, possible juvenile pilocytic astrocytoma
Size 5.5 X 3.3
Response 40-50% decrease of solid component
prior Treatment (Tx) vitamins and laetrile

5. Histology glioblastoma multiforme (GBM)
Size 6.5 x 5.0
Response 39% decrease
prior Treatment (Tx) Radiation Therapy (RT)

6. Histology glioma consistent with anaplastic astrocytoma (AA), differential: anaplastic astrocytoma or spindle cell variant of oligodendroglioma
Size 5.1 x 2.2
Response Complete Response (CR)
prior Treatment (Tx) Radiation Therapy (RT)

7. Histology Infiltrating anaplastic astrocytoma (AA)
Size 4.0 (L) 4.8 (bifrontal)
Response good response – possible Complete Response (CR)
prior Treatment (Tx) Radiation Therapy (RT)

1991 (10/4/1991) – site visit [3]